Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes

Next Previous
Trial Profile

A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin lispro (Primary) ; Insulin neutral protamine lispro (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms IOPJ
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 19 Jan 2022 This trial has been completed in Slovakia (End Date: 25 Feb 2010), according to European Clinical Trials Database record.
  • 16 Sep 2011 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.
  • 16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top